Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

EBioMedicine

Volumn 21, Issue , 2017, Pages 182-187

  Yakoot, Mostafa ^a   Abdo, Alaa M ^b   Abdel Rehim, Siham ^b   Helmy, Sherine ^c  

^a Green CRC and Abbas Helmy Clinics   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c Quality Control Department   (Egypt)

Author keywords

Chronic hepatitis C infection; Daclatasvir; Response tailored therapy; Sofosbuvir; SVR12; Very rapid virologic response

Indexed keywords

DAKTAVIRA; ELBASVIR PLUS GRAZOPREVIR; GRATISOVIR; LEDIPASVIR PLUS SOFOSBUVIR; BMS-790052; IMIDAZOLE DERIVATIVE; SOFOSBUVIR;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; CRITICALLY ILL PATIENT; EGYPTIAN; FEMALE; FOLLOW UP; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SCHISTOSOMIASIS; STUDY DESIGN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS INFECTION; VIRUS LOAD; YOUNG ADULT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; EGYPT; GENETICS; GENOTYPE; HEPACIVIRUS; TREATMENT OUTCOME; VIROLOGY;

ADULT; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 85020862639     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.05.011     Document Type: Article

References (12)

1. Alavian, S.M., Rezaee-Zavareh, M.S., Daclatasvir-based treatment regimens for hepatitis C virus infection: a systematic review and meta-analysis. Hepat. Mon., 16(9), 2016, e41077.
2. Curry, M., Modi, A.A., Pungpapong, S., Leise, M., Aqel, B., Llewellyn, J., et al. Realworld effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real-world cohorts. J. Hepatol., 64, 2016, S797.
3. Di Maio, V.C., Cento, V., Lenci, I., et al. HCV Italian resistance network study group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int., 2017, 10.1111/liv.13327 (Epub ahead of print).
4. D'Offizi, G., Cammà C., Taibi, C., et al. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection. New Microbiol. 40:1 (2017), 19–26.
5. European Association for the Study of the Liver, EASL recommendations on treatment of hepatitis C 2016. J. Hepatol. 66:1 (2017), 153–194.
6. Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370 (2014), 1879–1888.
7. Llaneras, J., Riveiro-Barciela, M., Buti, M., Esteban, R., Hepatitis C virus genotype 4: genotype 1's little brother. J. Viral Hepat. 24:1 (2017), 4–12.
8. Maasoumy, B., Vermehren, J., Welker, M.W., et al. Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens. J. Hepatol. 65:3 (2016), 473–482.
9. Pineda, J.A., Morano-Amado, L.E., Granados, R., et al. Grupo de Estudio de Hepatitis Vírica.; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC and Grupo de Estudio de Hepatitis Vírica.; Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR/Red de Investigación en SIDA (RIS-HEP07): Week 4-response predicts sustained virologic response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. Clin. Microbiol. Infect., 2017, 30005–30008 pii: S1198-743X (17).
10. Rockstroh, J.K., Ingiliz, P., Petersen, J., et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir. Ther., 2016, 10.3851/IMP3108 (Epub ahead of print).
11. Sulkowski, M.S., Flamm, S., Kayali, Z., et al. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir, and sofosbuvir (FOURward study). Liver Int., 2016, 10.1111/liv.13335 (Epub ahead of print).
12. Yakoot, M., Abdo, A.M., Yousry, A., Helmy, S., Very rapid virologic response and early HCV- response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy. Drug Des. Dev. Ther. 10 (2016), 2659–2667.